BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Aker S, Yilmaztepe A, Gurel S, Gulten M, Nak SG. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13(6): 837-844 [PMID: 17352011 DOI: 10.3748/wjg.v13.i6.837]
URL: https://www.wjgnet.com/1948-5182/full/v13/i6/837.htm
Number Citing Articles
1
Ciaran E. Fealy, Jacob M. Haus, Thomas P. J. Solomon, Mangesh Pagadala, Chris A. Flask, Arthur J. McCullough, John P. Kirwan. Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver diseaseJournal of Applied Physiology 2012; 113(1): 1 doi: 10.1152/japplphysiol.00127.2012
2
Людмила Владимировна Топчиева, Irina Kurbatova, Olga Dudanova, Alina Vasileva, Galina Zhulai. Immune cell balance as potential biomarker of progressing non-alcoholic fatty liver diseaseGenes & Cells 2024;  doi: 10.17816/gc610252
3
Carolina F. M. G. Pimentel, Zhenghui G. Jiang, Takeshi Otsubo, Linda Feldbrügge, Tracy L. Challies, Imad Nasser, Simon Robson, Nezam Afdhal, Michelle Lai. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASHDigestive Diseases and Sciences 2016; 61(3): 905 doi: 10.1007/s10620-015-3916-1
4
Yusuke Kawamura, Kenji Ikeda, Yasuji Arase, Shunichiro Fujiyama, Tetsuya Hosaka, Masahiro Kobayashi, Satoshi Saitoh, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada. New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver DiseaseInternal Medicine 2017; 56(12): 1459 doi: 10.2169/internalmedicine.56.7830
5
Zixiong Zhou, Jong Won Kim, Jing Zhao, Jing Qi, Seong Jin Choi, Chae Woong Lim, Moo-Yeol Lee, Kyuhong Lee, Bumseok Kim. Treatment of cigarette smoke extract and condensate differentially potentiates palmitic acid-induced lipotoxicity and steatohepatitis in vitroToxicology in Vitro 2018; 52: 33 doi: 10.1016/j.tiv.2018.05.017
6
Fatih Eren, Ramazan Kurt, Fatih Ermis, Ozlen Atug, Nese Imeryuz, Yusuf Yilmaz. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver diseaseClinical Biochemistry 2012; 45(9): 655 doi: 10.1016/j.clinbiochem.2012.03.019
7
Lei He, Linfeng Deng, Quan Zhang, Jianli Guo, Jinan Zhou, Wenjian Song, Fahu Yuan. Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-AnalysisBioMed Research International 2017; 2017: 1 doi: 10.1155/2017/9729107
8
Cristina Macía, Jose Loureiro, Isabel Campos-Varela, Ihab Abdulkader, Esteban Otero, Evaristo Varo, Santiago Tomé, Arturo Gonzalez-Quintela, Ned Snyder. Time-Course Changes of Serum Keratin Concentrations after Liver Transplantation: Contrasting Results of Keratin-18 and Keratin-19 FragmentsCase Reports in Hepatology 2020; 2020: 1 doi: 10.1155/2020/8895435
9
Constantinos Simopoulos, Alexandra K Tsaroucha, Byron Asimakopoulos, Alexandra Giatromanolaki, Paschalis Gavriilidis, Alexandros Polychronidis, Anastasios Karayiannakis. Total and caspase-cleaved cytokeratin 18 in chronic cholecystitis: A prospective studyBMC Gastroenterology 2008; 8(1) doi: 10.1186/1471-230X-8-14
10
Yvonne Alt, Anna Grimm, Liesa Schlegel, Annette Grambihler, Jens M. Kittner, Jörg Wiltink, Peter R. Galle, Marcus A. Wörns, Jörn M. Schattenberg, Matias A Avila. The Impact of Liver Cell Injury on Health-Related Quality of Life in Patients with Chronic Liver DiseasePLOS ONE 2016; 11(3): e0151200 doi: 10.1371/journal.pone.0151200
11
Arun Sanyal, Kenneth Cusi, Mark L Hartman, Shuyu Zhang, Edward J Bastyr, Juliana M Bue-Valleskey, Annette M Chang, Axel Haupt, Scott J Jacober, Robert J Konrad, Qianyi Zhang, Byron J Hoogwerf. Cytokeratin-18 and Enhanced Liver Fibrosis Scores in Type 1 and Type 2 Diabetes and Effects of Two Different InsulinsJournal of Investigative Medicine 2018; 66(3): 661 doi: 10.1136/jim-2017-000609
12
Naim Alkhouri, Christine Carter-Kent, Ariel E Feldstein. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implicationsExpert Review of Gastroenterology & Hepatology 2011; 5(2): 201 doi: 10.1586/egh.11.6
13
Leon A ADAMS, Ariel E FELDSTEIN. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitisJournal of Digestive Diseases 2011; 12(1): 10 doi: 10.1111/j.1751-2980.2010.00471.x
14
Dawn M. Torres, Stephen A. Harrison. Diagnosis and Therapy of Nonalcoholic SteatohepatitisGastroenterology 2008; 134(6): 1682 doi: 10.1053/j.gastro.2008.02.077
15
Bongkun Choi, Eun-Ju Chang. Biomarkers in Liver DiseaseBiomarkers in Disease: Methods, Discoveries and Applications 2016; : 1 doi: 10.1007/978-94-007-7742-2_32-1
16
Zobair M. Younossi, Mohammed Jarrar, Clare Nugent, Manpreet Randhawa, Mariam Afendy, Maria Stepanova, Nila Rafiq, Zachary Goodman, Vikas Chandhoke, Ancha Baranova. A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH)Obesity Surgery 2008; 18(11): 1430 doi: 10.1007/s11695-008-9506-y
17
N. J. BARSHOP, C. B. SIRLIN, J. B. SCHWIMMER, J. E. LAVINE. Review article: epidemiology, pathogenesis and potential treatments of paediatric non‐alcoholic fatty liver diseaseAlimentary Pharmacology & Therapeutics 2008; 28(1): 13 doi: 10.1111/j.1365-2036.2008.03703.x
18
Fataneh Amidi, Barbara A. French, David Chung, Charles H. Halsted, Valentina Medici, Samuel W. French. M-30 and 4HNE are sequestered in different aggresomesin the same hepatocytesExperimental and Molecular Pathology 2007; 83(3): 296 doi: 10.1016/j.yexmp.2007.09.001
19
Giovanni Musso, Roberto Gambino, Giovanni Pacini, Franco De Michieli, Maurizio Cassader. Prolonged saturated fat–induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liverThe American Journal of Clinical Nutrition 2009; 89(2): 558 doi: 10.3945/ajcn.2008.26720
20
Bongkun Choi, Eun-Ju Chang. Biomarkers in Liver DiseaseBiomarkers in Disease: Methods, Discoveries and Applications 2017; : 603 doi: 10.1007/978-94-007-7675-3_32
21
Y. YILMAZ. Systematic review: caspase‐cleaved fragments of cytokeratin 18 – the promises and challenges of a biomarker for chronic liver diseaseAlimentary Pharmacology & Therapeutics 2009; 30(11-12): 1103 doi: 10.1111/j.1365-2036.2009.04148.x
22
Krishna Sumanth Nallagangula, Shashidhar Kurpad Nagaraj, Lakshmaiah Venkataswamy, Muninarayana Chandrappa. Liver fibrosis: a compilation on the biomarkers status and their significance during disease progressionFuture Science OA 2018; 4(1): FSO250 doi: 10.4155/fsoa-2017-0083
23
Franck Brouillard, Janine Fritsch, Aleksander Edelman, Mario Ollero. Contribution of proteomics to the study of the role of cytokeratins in disease and physiopathologyPROTEOMICS – Clinical Applications 2008; 2(2): 264 doi: 10.1002/prca.200780018
24
J. Shen, H. L.‐Y. Chan, G. L.‐H. Wong, A. W.‐H. Chan, P. C.‐L. Choi, H.‐Y. Chan, A. M.‐L. Chim, D. K.‐W. Yeung, J. Yu, W. C.‐W. Chu, V. W.‐S. Wong. Assessment of non‐alcoholic fatty liver disease using serum total cell death and apoptosis markersAlimentary Pharmacology & Therapeutics 2012; 36(11-12): 1057 doi: 10.1111/apt.12091
25
Nafiseh Esmaeil, Behjat Moayedi, Marjan Gharagozloo, Mohamad Reza Maracy. Elevated Serum Levels of Cell Death Circulating Biomarkers, M30 and M65, In Patients with β-Thalassemia MajorHemoglobin 2013; 37(4): 404 doi: 10.3109/03630269.2013.790828
26
Yusuf Yilmaz, Ramazan Kurt, Cem Kalayci. Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragmentsBiomarkers in Medicine 2010; 4(5): 743 doi: 10.2217/bmm.10.65
27
J. Shen, V. W.‐S. Wong. Letter: diagnostic accuracy of M30 levels for identifying patients with non‐alcoholic steatohepatitis – authors’ replyAlimentary Pharmacology & Therapeutics 2013; 37(2): 283 doi: 10.1111/apt.12156
28
Michael H. Miller, Michael A. J. Ferguson, John F. Dillon. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver diseaseLiver International 2011; 31(4): 461 doi: 10.1111/j.1478-3231.2011.02451.x
29
Yusuf Yilmaz. Cytokeratins in hepatitisClinica Chimica Acta 2011; 412(23-24): 2031 doi: 10.1016/j.cca.2011.09.002
30
Leon A Adams, Ariel E Feldstein. Nonalcoholic steatohepatitis: risk factors and diagnosisExpert Review of Gastroenterology & Hepatology 2010; 4(5): 623 doi: 10.1586/egh.10.56
31
Naim Alkhouri, Anna Alisi, Vera Okwu, Ammar Matloob, Federica Ferrari, Annalisa Crudele, Rita De Vito, Rocio Lopez, Ariel E. Feldstein, Valerio Nobili. Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic SteatohepatitisDigestive Diseases and Sciences 2015; 60(8): 2353 doi: 10.1007/s10620-015-3614-z
32
Ying Shi, Shihui Sun, Yali Liu, Junfeng Li, Tong Zhang, Hao Wu, Xinyue Chen, Dexi Chen, Yusen Zhou. Keratin 18 phosphorylation as a progression marker of chronic hepatitis BVirology Journal 2010; 7(1) doi: 10.1186/1743-422X-7-70
33
Engin Ulukaya, Ceyda Acilan, Yusuf Yilmaz. Apoptosis: why and how does it occur in biology?Cell Biochemistry and Function 2011; 29(6): 468 doi: 10.1002/cbf.1774
34
Salvatore Petta, Aurora Giannetti. Non-Alcoholic Fatty Liver Disease2020; : 235 doi: 10.1007/978-3-319-95828-6_13
35
Ciro Celsa, Grazia Pennisi, Federica Spatola, Aurora Giannetti, Salvatore Petta. NAFLD and NASH2020; : 89 doi: 10.1007/978-3-030-37173-9_6
36
Yasar Colak, Ebubekir Senates, Oguzhan Ozturk, Yusuf Yilmaz, Ebru Zemheri, Feruze Yilmaz Enc, Celal Ulasoglu, Sebahat Aksaray, Sabriye Gulcin Bozbeyoglu, Safak Kiziltas, Oya Ovunc Kurdas, Ilyas Tuncer. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver diseaseEuropean Journal of Gastroenterology & Hepatology 2012; 24(3): 255 doi: 10.1097/MEG.0b013e32834e8041
37
Jenny Lee, Yasaman Vali, Jérôme Boursier, Kevin Duffin, Joanne Verheij, M. Julia Brosnan, Koos Zwinderman, Quentin M. Anstee, Patrick M. Bossuyt, Mohammad Hadi Zafarmand, Pavel Strnad. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysisPLOS ONE 2020; 15(9): e0238717 doi: 10.1371/journal.pone.0238717
38
Davide Festi, Ramona Schiumerini, Giovanni Marasco, Eleonora Scaioli, Francesca Pasqui, Antonio Colecchia. Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectivesExpert Review of Gastroenterology & Hepatology 2015; 9(8): 1039 doi: 10.1586/17474124.2015.1049155
39
Vaishali Patel, Arun J. Sanyal, Richard Sterling. Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver DiseaseClinics in Liver Disease 2016; 20(2): 277 doi: 10.1016/j.cld.2015.10.006
40
Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver DiseaseGastroenterology 2019; 156(5): 1264 doi: 10.1053/j.gastro.2018.12.036
41
Yusuf Yilmaz, Engin Ulukaya, Enver Dolar. A “Biomarker Biopsy” for the Diagnosis of NASH: Promises from CK-18 FragmentsObesity Surgery 2008; 18(11): 1507 doi: 10.1007/s11695-008-9639-z
42
Julien Calderaro, Elie Serge Zafrani. Stéatopathie hépatique non alcooliqueAnnales de Pathologie 2010; 30(6): 413 doi: 10.1016/j.annpat.2010.10.002
43
Yusuf Yilmaz, Fatih Eren. Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitisClinica Chimica Acta 2012; 414: 154 doi: 10.1016/j.cca.2012.08.005
44
Scott C. Beeman, Joel R. Garbow. Imaging and Metabolism2018; : 223 doi: 10.1007/978-3-319-61401-4_10
45
Mayumi TABUCHI, Kayoko TOMIOKA, Takayo KAWAKAMI, Yasuko MURAKAMI, Makoto HIRAMATSU, Tatsuya ITOSHIMA, Shiori SUGAWARA, Aiko KAWASHIMA, Misako OKITA, Ikuyo TSUKAMOTO. Serum Cytokeratin 18 M30 Antigen Level and Its Correlation with Nutritional Parameters in Middle-Aged Japanese Males with Nonalcoholic Fatty Liver Disease (NAFLD)Journal of Nutritional Science and Vitaminology 2010; 56(5): 271 doi: 10.3177/jnsv.56.271
46
Juan Pablo Arab, Cristián Hernández-Rocha, Carolina Morales, José Ignacio Vargas, Nancy Solís, Margarita Pizarro, Camila Robles, Daniela Sandoval, Simon Ponthus, Carlos Benítez, Francisco Barrera, Alejandro Soza, Arnoldo Riquelme, Marco Arrese. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the Chilean populationGastroenterología y Hepatología (English Edition) 2017; 40(6): 388 doi: 10.1016/j.gastre.2017.02.003
47
Jun Yu, Jiayun Shen, Ting Ting Sun, Xiang Zhang, Nathalie Wong. Obesity, insulin resistance, NASH and hepatocellular carcinomaSeminars in Cancer Biology 2013; 23(6): 483 doi: 10.1016/j.semcancer.2013.07.003
48
Billur Canbakan, Hakan Senturk, Mustafa Canbakan, Tayfur Toptas, Omur Tabak, Huriye Balci, Vakur Olgac, Gulsen Ozbay. Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease?Biomarkers in Medicine 2010; 4(2): 205 doi: 10.2217/bmm.09.88
49
Mariana V. Machado, Helena Cortez-Pinto. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisalJournal of Hepatology 2013; 58(5): 1007 doi: 10.1016/j.jhep.2012.11.021
50
Michael Fuchs, Arun J. Sanyal. The Liver2009; : 719 doi: 10.1002/9780470747919.ch45
51
Juan Pablo Arab, Cristián Hernández-Rocha, Carolina Morales, José Ignacio Vargas, Nancy Solís, Margarita Pizarro, Camila Robles, Daniela Sandoval, Simon Ponthus, Carlos Benítez, Francisco Barrera, Alejandro Soza, Arnoldo Riquelme, Marco Arrese. Fragmento sérico de citoqueratina-18 como marcador no invasivo de esteatohepatitis no alcohólica en población chilenaGastroenterología y Hepatología 2017; 40(6): 388 doi: 10.1016/j.gastrohep.2017.02.009
52
Jacquelyn J. Maher, Pablo Leon, James C. Ryan. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitisHepatology 2008; 48(2): 670 doi: 10.1002/hep.22399
53
Nora Anderson, Jürgen Borlak. Molecular Mechanisms and Therapeutic Targets in Steatosis and SteatohepatitisPharmacological Reviews 2008; 60(3): 311 doi: 10.1124/pr.108.00001
54
Tunay Senturk, Ali Aydinlar, Yusuf Yilmaz, Arzu Yilmaztepe Oral, Osman Ozdabakoglu, Engin Ulukaya. Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: relationship with the severity of coronary artery diseaseCoronary Artery Disease 2009; 20(8): 494 doi: 10.1097/MCA.0b013e328330d56a
55
Julia Kälsch, Lars P. Bechmann, Hagen Kälsch, Martin Schlattjan, Jochen Erhard, Guido Gerken, Ali Canbay. Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese PatientsJournal of Nutrition and Metabolism 2011; 2011: 1 doi: 10.1155/2011/369168
56
Pamela Valva, Paola Casciato, Carol Lezama, Marcela Galoppo, Adrián Gadano, Omar Galdame, María Cristina Galoppo, Eduardo Mullen, Elena De Matteo, María Victoria Preciado, Ravi Jhaveri. Serum Apoptosis Markers Related to Liver Damage in Chronic Hepatitis C: sFas as a Marker of Advanced Fibrosis in Children and Adults While M30 of Severe Steatosis Only in ChildrenPLoS ONE 2013; 8(1): e53519 doi: 10.1371/journal.pone.0053519
57
K Widhalm, E Ghods. Nonalcoholic fatty liver disease: a challenge for pediatriciansInternational Journal of Obesity 2010; 34(10): 1451 doi: 10.1038/ijo.2010.185
58
Briohny W. Smith, Leon A. Adams. Non-alcoholic fatty liver diseaseCritical Reviews in Clinical Laboratory Sciences 2011; 48(3): 97 doi: 10.3109/10408363.2011.596521
59
Wah-Kheong Chan, Pavai Sthaneshwar, Nik Raihan Nik Mustapha, Sanjiv Mahadeva, Anna Alisi. Limited Utility of Plasma M30 in Discriminating Non-Alcoholic Steatohepatitis from Steatosis – A Comparison with Routine Biochemical MarkersPLoS ONE 2014; 9(9): e105903 doi: 10.1371/journal.pone.0105903
60
Pamela Valva, Daniela A Ríos, Elena De Matteo, Maria V Preciado. Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damageWorld Journal of Gastroenterology 2016; 22(4): 1367-1381 doi: 10.3748/wjg.v22.i4.1367
61
Alastair Greystoke, Andrew Hughes, Malcolm Ranson, Caroline Dive, Jeff Cummings, Tim Ward. Serum biomarkers of apoptosisEuropean Journal of Cancer Supplements 2007; 5(5): 115 doi: 10.1016/S1359-6349(07)70032-0
62
Rabia Ergelen, Umit Akyuz, Yucel Aydin, Fatih Eren, Yusuf Yilmaz. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver diseaseEuropean Journal of Gastroenterology & Hepatology 2015; 27(6): 667 doi: 10.1097/MEG.0000000000000342
63
Sophia Heinrich, Thomas Austgen, Darko Castven, Moritz Hess, Christian Labenz, Martha Kirstein, Carolin Zimpel, Lena Stockhoff, Benjamin Maasoumy, Bernd Heinrich, Hans Heinrich Wedemeyer, Peter Robert Galle, Harald Binder, Marc Nguyen‐Tat, Jens Uwe Marquardt. Markers of cell death predict therapy response in patients with cirrhosis and hepatorenal syndromeUnited European Gastroenterology Journal 2023; 11(1): 92 doi: 10.1002/ueg2.12337
64
Naim Alkhouri, Ariel E. Feldstein. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?Metabolism 2016; 65(8): 1087 doi: 10.1016/j.metabol.2016.01.013
65
Andrew J Fowell, Kirsty Fancey, Karen Gamble, Kelly Bicknell, Joanna K Dowman, Paul Howden, Richard J Aspinall. Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver diseaseFrontline Gastroenterology 2021; 12(2): 102 doi: 10.1136/flgastro-2019-101304
66
Maurizio Soresi, Lydia Giannitrapani, Melchiorre Cervello, Anna Licata, Giuseppe Montalto. Non invasive tools for the diagnosis of liver cirrhosisWorld Journal of Gastroenterology 2014; 20(48): 18131-18150 doi: 10.3748/wjg.v20.i48.18131
67
Mohammad Safarian, Sepideh Mohammadpour, Mojtaba Shafiee, Azita Ganji, Anvar Soleimani, Mohsen Nematy, Ali Bahari. Effect of diet-induced weight loss on cytokeratin-18 levels in overweight and obese patients with liver fibrosisDiabetes & Metabolic Syndrome: Clinical Research & Reviews 2019; 13(2): 989 doi: 10.1016/j.dsx.2019.01.005
68
Arturo Gonzalez‐Quintela, Santiago Tomé, Carmen Fernandez‐Merino, Jesus Rey, Luis Meijide, Francisco Gude. Synergistic Effect of Alcohol Consumption and Body Mass on Serum Concentrations of Cytokeratin‐18Alcoholism: Clinical and Experimental Research 2011; 35(12): 2202 doi: 10.1111/j.1530-0277.2011.01570.x
69
David E. Amacher. Progress in the search for circulating biomarkers of nonalcoholic fatty liver diseaseBiomarkers 2014; 19(7): 541 doi: 10.3109/1354750X.2014.958535
70
Giovanni Musso, Roberto Gambino, Maurizio Cassader, Gianfranco Pagano. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severityAnnals of Medicine 2011; 43(8): 617 doi: 10.3109/07853890.2010.518623
71
Yusuf Yilmaz, Fatih Eren. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver diseaseEuropean Journal of Gastroenterology & Hepatology 2014; 26(11): 1292 doi: 10.1097/MEG.0000000000000184
72
Diana Joka, Kristin Wahl, Sarah Moeller, Jerome Schlue, Bernhard Vaske, Matthias J. Bahr, Michael P. Manns, Klaus Schulze-Osthoff, Heike Bantel. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitisHepatology 2012; 55(2): 455 doi: 10.1002/hep.24734
73
J. K. Dowman, J. W. Tomlinson, P. N. Newsome. Systematic review: the diagnosis and staging of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitisAlimentary Pharmacology & Therapeutics 2011; 33(5): 525 doi: 10.1111/j.1365-2036.2010.04556.x
74
M. Civera, A. Urios, M. L. Garcia‐Torres, J. Ortega, J. Martinez‐Valls, N. Cassinello, J. A. del Olmo, A. Ferrandez, J. M. Rodrigo, C. Montoliu. Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesityDiabetes/Metabolism Research and Reviews 2010; 26(3): 187 doi: 10.1002/dmrr.1070
75
Kai Liu, Jinli Lou, Tao Wen, Jiming Yin, Bin Xu, Wei Ding, Anna Wang, Daojie Liu, Chao Zhang, Dexi Chen, Ning Li. Depending on the stage of hepatosteatosis, p53 causes apoptosis primarily through either DRAM‐induced autophagy or BAXLiver International 2013; 33(10): 1566 doi: 10.1111/liv.12238
76
Ariel E Feldstein, Naim Alkhouri, Rita De Vito, Anna Alisi, Rocio Lopez, Valerio Nobili. Serum Cytokeratin-18 Fragment Levels Are Useful Biomarkers for Nonalcoholic Steatohepatitis in ChildrenAmerican Journal of Gastroenterology 2013; 108(9): 1526 doi: 10.1038/ajg.2013.168
77
Pamela Valva, Daniela Rios, Paola Casciato, Adrián Gadano, Omar Galdame, Eduardo Mullen, Gustavo Bertot, Elena de Matteo, María V. Preciado. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from ArgentinaEuropean Journal of Gastroenterology & Hepatology 2018; 30(6): 637 doi: 10.1097/MEG.0000000000001079
78
María Rubio-Murillo, Alejandro Rodríguez-Martínez. NAFLD and NASH2020; : 69 doi: 10.1007/978-3-030-37173-9_5
79
Pamela Valva, Elena De Matteo, María C. Galoppo, María I. Gismondi, María V. Preciado. Apoptosis markers related to pathogenesis of pediatric chronic hepatitis C virus infection: M30 mirrors the severity of steatosisJournal of Medical Virology 2010; 82(6): 949 doi: 10.1002/jmv.21699
80
Mitchell R. McGill, Benjamin L. Woolbright, James L. Weemhoff, Hartmut Jaeschke. Biomarkers in Liver DiseaseBiomarkers in Disease: Methods, Discoveries and Applications 2017; : 71 doi: 10.1007/978-94-007-7675-3_5
81
Eugenia Tsai, Tai-Ping Lee. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient ElastographyClinics in Liver Disease 2018; 22(1): 73 doi: 10.1016/j.cld.2017.08.004
82
Raj Vuppalanchi, Naga Chalasani. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and managementHepatology 2009; 49(1): 306 doi: 10.1002/hep.22603
83
Masaru Tsutsui, Naoki Tanaka, Masatomo Kawakubo, Yo Sheena, Akira Horiuchi, Michiharu Komatsu, Tadanobu Nagaya, Satoru Joshita, Takeji Umemura, Tetsuya Ichijo, Akihiro Matsumoto, Kaname Yoshizawa, Toshifumi Aoyama, Eiji Tanaka, Kenji Sano. Serum Fragmented Cytokeratin 18 Levels Reflect the Histologic Activity Score of Nonalcoholic Fatty Liver Disease More Accurately Than Serum Alanine Aminotransferase LevelsJournal of Clinical Gastroenterology 2010; 44(6): 440 doi: 10.1097/MCG.0b013e3181bdefe2
84
Jing Chen, Yueyong Zhu, Qi Zheng, Jiaji Jiang. Serum cytokeratin‐18 in the diagnosis of non‐alcoholic steatohepatitis: A meta‐analysisHepatology Research 2014; 44(8): 854 doi: 10.1111/hepr.12197
85
Y. Yilmaz. Letter: diagnostic accuracy of M30 levels for identifying patients with non‐alcoholic steatohepatitisAlimentary Pharmacology & Therapeutics 2013; 37(2): 283 doi: 10.1111/apt.12142
86
Bryan D. Maliken, James E. Nelson, Heather M. Klintworth, Mary Beauchamp, Matthew M. Yeh, Kris V. Kowdley. Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver diseaseHepatology 2013; 57(5): 1806 doi: 10.1002/hep.26238
87
Mitchell R. McGill, Benjamin L. Woolbright, James L. Weemhoff, Hartmut Jaeschke. Biomarkers in Liver DiseaseBiomarkers in Disease: Methods, Discoveries and Applications 2016; : 1 doi: 10.1007/978-94-007-7742-2_5-1
88
Dulshan Jayasekera, Phillipp Hartmann. Noninvasive biomarkers in pediatric nonalcoholic fatty liver diseaseWorld Journal of Hepatology 2023; 15(5): 609-640 doi: 10.4254/wjh.v15.i5.609
89
Hazem Abd-Elgawad, Nashwa Abu-Elsaad, Amr El-Karef, Tarek Ibrahim. Piceatannol increases the expression of hepatocyte growth factor and IL-10 thereby protecting hepatocytes in thioacetamide-induced liver fibrosisCanadian Journal of Physiology and Pharmacology 2016; 94(7): 779 doi: 10.1139/cjpp-2016-0001
90
Sezgin Ulukaya, Engin Ulukaya, Isik Alper, Arzu Yilmaztepe‐Oral, Murat Kilic. Soluble cytokeratin 18 biomarkers may provide information on the type of cell death during early ischemia and reperfusion periods of liver transplantationClinical Transplantation 2010; 24(6): 848 doi: 10.1111/j.1399-0012.2009.01177.x
91
Fatih Eren, Yusuf Yilmaz, Sukran Kose, Filiz Ture Ozdemir, Oya Yonal, Ramazan Kurt, Osman Ozdogan, Erol Avsar. Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis BClinica Chimica Acta 2010; 411(23-24): 2029 doi: 10.1016/j.cca.2010.08.035
92
Joanne R. Morling, Jonathan A. Fallowfield, Rachel M. Williamson, Lisa D. Nee, Andrew P. Jackson, Stephen Glancy, Rebecca M. Reynolds, Peter C. Hayes, Indra N. Guha, Mark W. J. Strachan, Jackie F. Price. Non‐invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes studyLiver International 2014; 34(8): 1267 doi: 10.1111/liv.12385
93
Ariel E. Feldstein, Anna Wieckowska, A. Rocio Lopez, Yao-Chang Liu, Nizar N. Zein, Arthur J. McCullough. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation studyHepatology 2009; 50(4): 1072 doi: 10.1002/hep.23050
94
Jeffrey R. Lewis, Smruti R. Mohanty. Nonalcoholic Fatty Liver Disease: A Review and UpdateDigestive Diseases and Sciences 2010; 55(3): 560 doi: 10.1007/s10620-009-1081-0
95
Danielle Adebayo, Vincenzo Morabito, Fausto Andreola, Giulia Pieri, Tu‐Vin Luong, Amar Dhillon, Rajeshwar Mookerjee, Rajiv Jalan. Mechanism of cell death in acute‐on‐chronic liver failure: a clinico‐pathologic‐biomarker studyLiver International 2015; 35(12): 2564 doi: 10.1111/liv.12850
96
Miwa Kawanaka, Ken Nishino, Jun Nakamura, Noriyo Urata, Takahito Oka, Daisuke Goto, Mitsuhiko Suehiro, Hirofumi Kawamoto, Gotaro Yamada. Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver diseaseAnnals of Hepatology 2015; 14(6): 837 doi: 10.5604/16652681.1171767
97
Ankita Singh, Vipul Ranjan, Rina Das, Karun Bhatti, Dinesh Kumar Mehta, Ram Mohan Chidurala. Serum Biomarkers for Noninvasive Diagnosis of Liver Diseases: How Laudable are These Tools?Current Chemical Biology 2021; 15(2): 128 doi: 10.2174/2212796814999201111204639
98
Shiori Sugawara, Takemi Akahane, Kennichi Fukui, Ikuyo Tsukamoto. Association of Serum CK18 M30 Antigen Level with Food Intake in Middle-aged Japanese MenNippon Eiyo Shokuryo Gakkaishi 2014; 67(3): 127 doi: 10.4327/jsnfs.67.127
99
Mesbah Uddin Ahmed. Association of Serum Cytokeratin-18 Fragment Concentration in Patients with Different Types of Nonalcoholic Fatty Liver DiseaseGastroenterology & Hepatology : Open Access 2015; 2(2) doi: 10.15406/ghoa.2015.02.00037
100
Steven J. Potts, Johanna K. DiStefano. Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic DevelopmentMethods in Pharmacology and Toxicology 2014; : 101 doi: 10.1007/7653_2014_29
101
Yusuf Yilmaz, Engin Ulukaya, Enver Dolar. Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levelsHepatology 2009; 49(2): 697 doi: 10.1002/hep.22691
102
Henryk Dancygier. Clinical Hepatology2010; : 1153 doi: 10.1007/978-3-642-04519-6_35
103
Luca Maccioni, Yves Horsmans, Isabelle Leclercq, Bernd Schnabl, Peter Stärkel. Serum keratin 18‐M65 levels detect progressive forms of alcohol‐associated liver disease in early noncirrhotic stagesAlcohol: Clinical and Experimental Research 2023; 47(6): 1079 doi: 10.1111/acer.15081
104
Vlad Ratziu, Laurence Martin, Larysa Fedchuk, Thierry Poynard. Can nonalcoholic steatohepatitis be diagnosed without liver biopsy?Biomarkers in Medicine 2009; 3(4): 353 doi: 10.2217/bmm.09.36
105
R. Kwok, Y.‐K. Tse, G. L.‐H. Wong, Y. Ha, A. U. Lee, M. C. Ngu, H. L.‐Y. Chan, V. W.‐S. Wong. Systematic review with meta‐analysis: non‐invasive assessment of non‐alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin‐18 fragmentsAlimentary Pharmacology & Therapeutics 2014; 39(3): 254 doi: 10.1111/apt.12569
106
Guofeng Ding, Zhi Li, Lei Zhang, Hui Ma, Hui Li. Circulating full‐length cytokeratin 18 for predicting prognosis of hepatitis B virus‐related acute‐on‐chronic liver failure patients with lamivudine treatmentHepatology Research 2016; 46(4): 329 doi: 10.1111/hepr.12549
107
Gamal Shiha, Nasser Mousa. Liver Diseases2020; : 427 doi: 10.1007/978-3-030-24432-3_36
108
Sudeep Tanwar, Paul M. Trembling, Indra N. Guha, Julie Parkes, Philip Kaye, Alastair D. Burt, Stephen D. Ryder, Guruprasad P. Aithal, Christopher P. Day, William M. Rosenberg. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver diseaseHepatology 2013; 57(1): 103 doi: 10.1002/hep.26030
109
John Richard, Ildiko Lingvay. Hepatic steatosis and Type 2 diabetes: current and future treatment considerationsExpert Review of Cardiovascular Therapy 2011; 9(3): 321 doi: 10.1586/erc.11.15
110
Yusuf Yilmaz, Engin Ulukaya, Enver Dolar. The quest for liver fibrosis biomarkers: Promises from the enhanced liver fibrosis panel and beyondHepatology 2009; 49(3): 1056 doi: 10.1002/hep.22608
111
Takeshi Okanoue, Atsushi Umemura, Kohichiroh Yasui, Yoshito Itoh. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in JapanJournal of Gastroenterology and Hepatology 2011; 26(s1): 153 doi: 10.1111/j.1440-1746.2010.06547.x
112
Dina G. Tiniakos, George V. Papatheodoridis. Serum markers of hepatocyte apoptosis: Current terminology and predictability in clinical practiceHepatology 2010; 51(2): 717 doi: 10.1002/hep.23251
113
Angeliki Papachristodoulou, Dimitrios Kavvadas, Athanasios Karamitsos, Theodora Papamitsou, Maria Chatzidimitriou, Antonia Sioga. Diagnosis and Staging of Pediatric Non-Alcoholic Fatty Liver Disease: Is Classical Ultrasound the Answer?Pediatric Reports 2021; 13(2): 312 doi: 10.3390/pediatric13020039
114
M. H. Miller, J. F. Dillon. Commentary: assessment of non‐alcoholic fatty liver disease using serum total cell death and apoptosis markersAlimentary Pharmacology & Therapeutics 2013; 37(2): 275 doi: 10.1111/apt.12134
115
Pauline Verhaegh, Roisin Bavalia, Bjorn Winkens, Ad Masclee, Daisy Jonkers, Ger Koek. Noninvasive Tests Do Not Accurately Differentiate Nonalcoholic Steatohepatitis From Simple Steatosis: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology 2018; 16(6): 837 doi: 10.1016/j.cgh.2017.08.024
116
Steven G Pearce, Nirav C Thosani, Jen-Jung Pan. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLDBiomarker Research 2013; 1(1) doi: 10.1186/2050-7771-1-7
117
Zeynep Hünkerler, Tülay Köken, Buğra Koca, Ahmet Kahraman. Role of Uremic Toxins on Apoptosis With Varying Periods of HemodialysisTherapeutic Apheresis and Dialysis 2017; 21(1): 38 doi: 10.1111/1744-9987.12504
118
Ancha Baranova, Zobair M. Younossi. Reply to the Letter to the Editor: “A “Biomarker Biopsy” for the Diagnosis of NASH: Promises from CK-18 Fragments” by Yusuf Yilmaz, Engin Ulukaya, Enver DolarObesity Surgery 2008; 18(11): 1509 doi: 10.1007/s11695-008-9641-5
119
George V. Papatheodoridis, Emilia Hadziyannis, Emmanuel Tsochatzis, Anastasia Georgiou, Georgia Kafiri, Dina G. Tiniakos, Katerina Margariti, Spilios Manolakopoulos, Emanuel K. Manesis, Athanasios J. Archimandritis. Serum Apoptotic Caspase Activity in Chronic Hepatitis C and Nonalcoholic Fatty Liver DiseaseJournal of Clinical Gastroenterology 2010; 44(4): e87 doi: 10.1097/MCG.0b013e3181c0945a
120
A. Gonzalez-Quintela, I. Abdulkader, J. Campos, L. Fernandez-Hernandez, S. Lojo. Serum Levels of Keratin-18 Fragments [Tissue Polypeptide-Specific Antigen (TPS)] Are Correlated with Hepatocyte Apoptosis in Alcoholic HepatitisDigestive Diseases and Sciences 2009; 54(3): 648 doi: 10.1007/s10620-008-0371-2
121
Mitchell R. McGill, Hartmut Jaeschke. Drug-induced Liver InjuryAdvances in Pharmacology 2019; 85: 221 doi: 10.1016/bs.apha.2019.02.001
122
Iradj Maleki, Mahmood Reza Aminafshari, Tarang Taghvaei, Vahid Hosseini, Alireza Rafiei, Zhila Torabizadeh, Maryam Barzin, Elahe Orang. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver diseaseWorld Journal of Gastroenterology 2014; 20(35): 12566-12573 doi: 10.3748/wjg.v20.i35.12566
123
Helena Cortez-Pinto, Mariana Machado. Impact of body weight, diet and lifestyle on nonalcoholic fatty liver diseaseExpert Review of Gastroenterology & Hepatology 2008; 2(2): 217 doi: 10.1586/17474124.2.2.217
124
Karel Dvorak, Jan Stritesky, Jaromir Petrtyl, Libor Vitek, Renata Sroubkova, Martin Lenicek, Vaclav Smid, Martin Haluzik, Radan Bruha, Pavel Strnad. Use of Non-Invasive Parameters of Non-Alcoholic Steatohepatitis and Liver Fibrosis in Daily Practice - An Exploratory Case-Control StudyPLoS ONE 2014; 9(10): e111551 doi: 10.1371/journal.pone.0111551
125
Andreas E Kremer, Christian Rust, Peter Eichhorn, Ulrich Beuers, Stefan Holdenrieder. Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markersExpert Review of Molecular Diagnostics 2009; 9(2): 139 doi: 10.1586/14737159.9.2.139
126
Mikako Obika, Hirofumi Noguchi. Diagnosis and Evaluation of Nonalcoholic Fatty Liver DiseaseExperimental Diabetes Research 2012; 2012: 1 doi: 10.1155/2012/145754
127
Yusuf Yilmaz. “Defragmenting” the noninvasive diagnosis of nonalcoholic steatohepatitis: Hopes from cytokeratin-18Hepatology 2009; 50(3): 990 doi: 10.1002/hep.23065
128
Matt Cave, Keith Cameron Falkner, Latasha Henry, Brittany Costello, Bonnie Gregory, Craig J. McClain. Serum Cytokeratin 18 and Cytokine Elevations Suggest A High Prevalence of Occupational Liver Disease in Highly Exposed Elastomer/Polymer WorkersJournal of Occupational & Environmental Medicine 2011; 53(10): 1128 doi: 10.1097/JOM.0b013e31822cfd68
129
S Lefere, F Van de Velde, L Devisscher, M Bekaert, S Raevens, X Verhelst, Y Van Nieuwenhove, M Praet, A Hoorens, C Van Steenkiste, H Van Vlierberghe, B Lapauw, A Geerts. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver diseaseInternational Journal of Obesity 2017; 41(8): 1207 doi: 10.1038/ijo.2017.102
130
Lei Fu, Nurdan Guldiken, Katharina Remih, Anna Sophie Karl, Christian Preisinger, Pavel Strnad. Serum/Plasma Proteome in Non-Malignant Liver DiseaseInternational Journal of Molecular Sciences 2024; 25(4): 2008 doi: 10.3390/ijms25042008
131
Gerald Denk, Ahmed‐Jawid Omary, Florian Paul Reiter, Simon Hohenester, Ralf Wimmer, Stefan Holdenrieder, Christian Rust. Soluble intracellular adhesion molecule, M30 and M65 as serum markers of disease activity and prognosis in cholestatic liver diseasesHepatology Research 2014; 44(13): 1286 doi: 10.1111/hepr.12304